Morgan Stanley Eyenovia, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Eyenovia, Inc. stock. As of the latest transaction made, Morgan Stanley holds 146,212 shares of EYEN stock, worth $95,037. This represents 0.0% of its overall portfolio holdings.

Number of Shares

146,212

Previous 102,392 42.8%

Holding current value

$95,037

Previous $212,000 32.08%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.99 - $2.37 $43,381 - $103,853	43,820 Added 42.8%	146,212 $144,000
Q4 2023 Feb 13, 2024	BUY	$1.08 - $2.08 $82,216 - $158,342	76,126 Added 289.83%	102,392 $212,000
Q3 2023 Nov 15, 2023	SELL	$1.57 - $2.54 $8,066 - $13,050	-5,138 Reduced 16.36%	26,266 $43,000
Q2 2023 Aug 14, 2023	BUY	$2.21 - $5.75 $54,080 - $140,708	24,471 Added 352.96%	31,404 $74,000
Q1 2023 May 15, 2023	BUY	$1.72 - $3.53 $4,497 - $9,230	2,615 Added 60.56%	6,933 $24,000

Q4 2022 Feb 14, 2023	BUY	$1.54 - $2.06 $26 - $35	17 Added 0.4%	4,318 $7,000
Q3 2022 Nov 14, 2022	BUY	$1.55 - $2.48 $1 - $2	1 Added 0.02%	4,301 $8,000
Q2 2022 Oct 27, 2022	SELL	$1.71 - $3.26 $1,060 - $2,021	-620 Reduced 12.6%	4,300 $8,000
Q2 2022 Aug 15, 2022	SELL	$1.71 - $3.26 $1,060 - $2,021	-620 Reduced 12.6%	4,300 $8,000
Q1 2022 Oct 27, 2022	BUY	$2.66 - $3.99 $1,649 - $2,473	620 Added 14.42%	4,920 $15,000
Q1 2022 May 13, 2022	BUY	$2.66 - $3.99 $5,107 - $7,660	1,920 Added 64.0%	4,920 $15,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $6.58 $920 - $1,730	-263 Reduced 8.06%	3,000 $12,000
Q3 2021 Nov 15, 2021	BUY	$3.97 - $5.64 $12,954 - $18,403	3,263 New	3,263 $16,000

Others Institutions Holding EYEN

# of Institutions

Shares Held

7.63M

Call Options Held

22.1K

Put Options Held

9.1K

View Full List

About EYENOVIA, INC.

Ticker EYEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,212,900
Market Cap $22.2M
Description
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the develop...

More about EYEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account